Cosentino's SPECIALTY CARE

RHEUMATOID ARTHRITIS SPECIALTY CARE PROGRAM

Phone: **833-796-6470** • Fax: **844-841-3401**

KLOUDSCRIPT Community Led Specialty Pharmacy Care

1 PATIENT INFORMATION:

Name: _____
Address: _____
City: _____ State: ____ Zip: _____
Phone: _____ Alt. Phone: _____
Email: _____
DOB: _____ Gender: ❍ M ❍ F Caregiver: _____
Height: _____ Weight: _____ Allergies: _____

2 PRESCRIBER INFORMATION:

Name: _____
Address: _____
City: _____ State: ____ Zip: _____
Phone: _____ Fax: _____
NPI: _____ DEA: _____
Tax I.D.: _____
Office Contact: _____ Phone: _____

3 STATEMENT OF MEDICAL NECESSITY: (Please Attach All Medical Documentation)

Date of Diagnosis: _____
ICD-10: _____
Other: _____
TB Test: ❑ Positive ❑ Negative Date: _____

Patient also taking Methotrexate? ❑ Yes ❑ No
Serious or active infection present? ❑ Yes ❑ No
Hep B ruled out or treatment started? ❑ Yes ❑ No
Does patient have latex allergy? ❑ Yes ❑ No
LFT: ALT:_____ AST:_____ Date:_____

Prior Failed Treatments:

❑ Azulfidine® ❑ Celebrex® ❑ Methotrexate
❑ Biologics ❑ Corticosteroids ❑ Others
❑ Calcipotriene ❑ Indocin®

Indicate Drug Name and Length of Treatment:

_____
_____
_____

If Prior Authorization is denied, recommended formulary alternatives will be provided to the prescriber based upon the patient's insurance coverage.

4 INJECTION TRAINING:

❍ To Be Administered by Pharmacist (State of Missouri Only) ❍ Pharmacist to Provide Training ❍ Patient Trained in MD Office ❍ Manufacturer Nurse Support

5 PICK UP OR DELIVERY:

❍ Delivery to Patient's Home ❍ Delivery to Physician's Office ❍ Pharmacy to Coordinate

6 INSURANCE INFORMATION: Please Include Front and Back Copies of Pharmacy and Medical Card

PRESCRIPTION INFORMATION: (Please be sure to choose both induction and maintenance dose where applicable)

Patient Name: _____ Patient's Date of Birth: _____

Medication	Dosage & Strength	Direction	QTY	Refills
❑ ACTEMRA®	❑ 162mg/0.9ml Prefilled Syringe ❑ 162mg/0.9ml Prefilled Autoinjector (ACTPen™)	❑ Inject 162mg SC every other week, followed by an increase to every week based on clinical response (Adults < 220 lbs) ❑ Inject 162mg SC every week (Adults > 220 lbs or Patients with SJIA > 66 lbs) ❑ Inject 162mg SC every 2 weeks (Patients with SJIA < 66 lbs or Patients with PJIA > 66 lbs) ❑ Inject 162mg SC every 3 weeks (Patients with PJIA < 66 lbs)		
❑ CIMZIA®	❑ Prefilled Syringe Starter Kit ❑ 200mg/ml Prefilled Syringe ❑ 200mg Lyophilized Powder Vial	❑ **Induction Dose:** Inject 400mg SC on day 1, day 14 and day 28	6	0
		❑ **Maintenance:** Inject 400mg SC every 4 weeks ❑ **Maintenance:** Inject 200mg SC every other week	2	
❑ COSENTYX®	❑ 150mg/ml Sensoready® Pen ❑ 150mg/ml Prefilled Syringe ❑ 150mg/ml Lyophilized Powder Vial	❑ **Induction Dose:** Inject 150mg SC at weeks 0, 1, 2, 3, and 4	5	0
		❑ **Induction Dose:** Inject 300mg SC at weeks 0, 1, 2, 3, and 4	10	0
		❑ **Maintenance Dose:** Inject 150mg SC every four weeks	1	
		❑ **Maintenance Dose:** Inject 300mg SC every four weeks	2	
❑ ENBREL®	❑ 50mg/ml Sureclick Autoinjector ❑ 50mg/ml Enbrel Mini™ Prefilled Cartridge ❑ *For Enbrel Mini™ only: AutoTouch™ Autoinjector* ❑ 50mg/ml Prefilled Syringe ❑ 25mg/0.5ml Prefilled Syringe ❑ 25mg/ml Vial			
		❑ Inject 50mg SC once a week	4	
		❑ Inject 25mg SC twice a week (3-4 days apart)	1	
		❑ Other_____		
❑ HUMIRA®	❑ 40mg/0.4ml Pen ❑ 40mg/0.4ml Prefilled Syringe ❑ 40mg/0.8ml Pen ❑ 40mg/0.8ml Prefilled Syringe	❑ Inject 40mg SC every other week ❑ Inject 40mg SC once a week ❑ *Patient has signed HUMIRA Complete form* *All strengths and dosages listed are Humira® Citrate Free*		
❑ KEVZARA®	❑ 150mg/1.14ml Prefilled Syringe ❑ 150mg/1.14ml Prefilled Pen ❑ 200mg/1.14ml Prefilled Syringe ❑ 200mg/1.14ml Prefilled Pen	❑ Inject 150mg SC every 2 weeks	2	
		❑ Inject 200mg SC every 2 weeks	2	
❑ OLUMIANT®	❑ 2mg Tablet	❑ Take 1 tablet by mouth with or without food daily	30	
❑ ORENCIA®	❑ 250mg Lyophilized Powder Vial ❑ 125mg/ml ClickJect™ Autoinjector ❑ 50mg/0.4ml Prefilled Syringe ❑ 87.5mg/0.7ml Prefilled Syringe ❑ 125mg/ml Prefilled Syringe	❑ **Induction Dose:** Patient Weight < 132 lbs: 500mg; 132-220 lbs: 750mg; > 220 lbs: 1000mg administered IV, then inject 125mg SC within 24 hours		0
		❑ Inject 50mg SC once a week (10 to less than 25kg)	4	
		❑ Inject 87.5mg SC once a week (25 to less than 50kg)	4	
		❑ Inject 125mg SC once a week (50kg or more)	4	
❑ OTEZLA® (for PsA)	❑ Starter Pack (Titration) ❑ 30mg Tablets	❑ **Starter Pack:** Take one tablet in the morning on day 1, then take one tablet in the morning and one tablet in the evening as directed on the starter pack	1	0
		❑ **Maintenance:** Take one 30mg tablet by mouth twice daily	60	
❑ SIMPONI®	❑ 50mg/0.5ml Smartject Autoinjector ❑ 50mg/0.5ml Prefilled Syringe	❑ Inject 50mg SC once a month	1	
❑ STELARA® (for PsA)	❑ 45mg/0.5ml Prefilled Syringe (for < 220 lbs) ❑ 45mg/0.5ml Vial ❑ 90mg/1ml Prefilled Syringe (for > 220 lbs) ❑ Yes or ❑ No: ***STELARA SELF-INJECTION:*** *Healthcare provider certifies that patient has been trained and is eligible for self-injection*	❑ **Induction Dose:** Inject 1 prefilled syringe SC on day 1	1	0
		❑ **Maintenance:** Inject 1 prefilled syringe SC on day 29, and every 12 weeks thereafter	1	
❑ TALTZ®	❑ 80mg/ml Single-Dose Prefilled Autoinjector ❑ 80mg/ml Single-Dose Prefilled Syringe	❑ **Induction Dose:** Inject 160mg SC (two 80mg injections) at weeks 0	2	0
		❑ **Maintenance:** Inject 80mg SC every 4 weeks	1	
❑ XELJANZ® ❑ XELJANZ® XR	❑ 5mg Tablet ❑ 11mg Tablet	❑ Take one 5mg tablet by mouth twice a day	60	
		❑ Take one 11mg tablet once a day	30	
❑ RASUVO® ❑ COLCIGEL® ❑ _____	❑ _____ ❑ _____ ❑ _____	❑ _____ ❑ _____ ❑ _____		

PRESCRIBER SIGNATURE:

I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services and patient assistance programs.

Signature: _____ Date: _____ Signature: _____ Date: _____

Substitution Permitted **Dispense As Written**

Prior authorization approval and insurance benefits will be determined by the payor based upon the patient's eligibility, medical necessity, and the terms of the patient's coverage, among other things. Participation in this program is not a guarantee of prior authorization or of payment.

v10.3_030819